ArticleScientific reports2025
Enhancing bioactivity and bioavailability of Limonium bellidifolium via cyclodextrin-based inclusion complexes: a new strategy in drug discovery from halophyte source.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study we investigated the enhancement of solubility, stability, and bioavailability of phytochemicals from Limonium bellidifolium using α- and β-cyclodextrin-based encapsulation. Ethanol/water extracts were encapsulated at 25 °C, 40 °C, and 60 °C, and their performance was evaluated through simulated in vitro gastrointestinal digestion. Optimal results were observed at 25 °C for β-cyclodextrin and at 40 °C for α-cyclodextrin. Structural analysis with FTIR and SEM confirmed minimal chemical changes and well-formed particles. Bioavailability tests revealed significantly higher recovery of major compounds, such as quercetin, catechin, and ferulic acid, in encapsulated samples compared to pure extracts. Both α- and β-cyclodextrin systems provided strong protection during digestion and retained a higher proportion of bioactives. Antioxidant assays showed increased activity after digestion in encapsulated forms, especially in aerial and root extracts. Enzyme inhibition tests demonstrated notable tyrosinase and acetylcholinesterase activity, particularly in β-cyclodextrin-encapsulated root extracts. These results confirm the effectiveness of cyclodextrin encapsulation in improving compound retention and biological activity. To our knowledge this is the first detailed report on L. bellidifolium encapsulation using cyclodextrins and offers a promising strategy for developing phytochemical delivery systems for therapeutic and nutraceutical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.